Fig. 2From: Cefoxitin versus carbapenems as definitive treatment for extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteremia in intensive care unit: a propensity-matched retrospective analysisKaplan–Meier survival curves for baseline population (A) and PS-matched patients (B) receiving cefoxitin or carbapenem therapy for extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniaeBack to article page